Delivery Order SPE2DR25D3012-SPE2DR26F4F2E
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,041.80 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with performance completed in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract awarded on January 9, 2026, with an ultimate completion date of January 12, 2026. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,020.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on January 15, 2026, with completion scheduled for January 16, 2026. The award was made on a non-set-aside, competitive basis to the Conshohocken, Pennsylvania-based pharmaceutical distributor. This delivery order represents a task order under AmerisourceBergen's parent company, Cencora, Inc.'s, significantly larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,410.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of January 20, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,661.23 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with performance at the company's Conshohocken, Pennsylvania facility. This non-competitive delivery order, awarded January 16, 2026, represents a task order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The parent company, Cencora, Inc., holds a significant $999,999,999.00 IDC...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- The Defense Logistics Agency awarded a $14,935.86 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of December 19, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,020.90 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on December 9, 2025, with completion scheduled for December 10, 2025. This non-competitive, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at its...
- The Defense Logistics Agency awarded a delivery order valued at $1,265.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. The contract represents a firm fixed price, non-set-aside delivery order executed on September 12, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award is a child contract under AmerisourceBergen's substantial $999,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $1,150.32 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price procurement with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4F2EDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,041.80 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of January 21, 2026. This is a firm fixed-price, non-set-aside contract executed on January 20, 2026, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates proven capability to deliver a comprehensive range of pharmaceutical products across multiple therapeutic domains through competitively awarded contracts. This delivery order for insulin medication reflects the company's ongoing role in supplying essential diabetes and endocrinology treatments to support Department of Defense healthcare requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 1/19/26 |